查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
基于人工智能的临床试验解决方案提供商的市场规模、份额和趋势分析：按治疗用途、临床试验阶段、最终用途、地区、细分市场预测（2022-2030 年）
市场调查报告书
商品编码
1097000

基于人工智能的临床试验解决方案提供商的市场规模、份额和趋势分析：按治疗用途、临床试验阶段、最终用途、地区、细分市场预测（2022-2030 年）

AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report By Therapeutic Application, By Clinical Trial Phase, By End-use, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 118 Pages | 商品交期: 2-10个工作天内

价格

基于人工智能的临床试验解决方案提供商市场的增长和趋势

正观研究最新报告显示，到 2030 年，全球基于 AI 的临床试验解决方案提供商市场规模将达到 78 亿美元，预测期内復合年增长率为 22.0%。预计会扩大。

人工智能是一种多功能工具，被用于提高药物发现研究的运营效率并加速药物发现过程。它也被高度采用以最小化药物开发过程的成本。各种学术界和製药公司都在积极采用基于人工智能的平台和技术。例如，2020 年 1 月，拜耳与一家总部位于英国的 AI 药物发现公司合作，利用 AI 药物发现平台开展了一项初步研究项目。此外，支持研发的公私合作努力以及人工智能在药物研究领域提供的多样化应用正在推动增长。

基于临床试验阶段，由于药物发现的增加和二期的大量活跃研究，二期将在 2021 年以 47.2% 的份额主导市场。此外，在整个临床试验阶段，越来越多地采用基于人工智能的工具进行数据收集和对总体预期结果的即时分析，这也促进了细分市场的增长。此外，该细分市场的收入份额更高，因为它可以在此阶段改进、确定和验证基于 AI 的工具的措施。

2021 年，基于治疗应用，肿瘤学在基于 AI 的临床试验解决方案提供商市场的收入份额最高。全球癌症发病率的增加以及肿瘤学领域药物研究数量的增加正在促进人工智能技术的引入。此外，越来越多的参与者正在开发和采用先进的基于肿瘤学的人工智能工具进行药物研究，这推动了细分市场的增长。

2021 年，基于最终用途，製药公司在市场上的收入份额最高。诊断和生物标誌物的更好开发、新药物靶点的识别以及领先製药公司在药物开发和药物测试的整个过程中更多地采用基于人工智能的技术是细分市场增长的关键驱动力之一。此外，这些领先的製药公司正在与人工智能供应商合作，在其研发和整体药物发现过程中利用人工智能技术，从而推动增长。

北美在市场上占主导地位，2021 年的收入份额为 43.8%。这一优势是由于该地区的初创企业数量不断增加。例如，Bullfrog AI 是一家美国初创公司，开发 bfLEAP，这是一个独特的人工智能平台，可以实现精准医疗。提高对基于人工智能的技术的认识和采用以增强药物研究成果正在推动该地区的市场增长。此外，政府加大支持和大公司的战略努力正在推动该地区对基于人工智能的临床试验解决方案的需求。

随着 COVID-19 的爆发，基于 AI 的技术的采用率激增。越来越多地采用技术先进的解决方案进行药物开发和分析采用的患者数据，推动了人工智能解决方案的采用激增。此外，在大流行期间，许多药物开发过程被搁置。因此，市场上的许多主要参与者已将重点转移到利用基于人工智能的解决方案上，从而推动分布式药物测试。此外，通过这些解决方案对大量患者数据进行有效分析有助于市场增长。

基于人工智能的临床试验解决方案提供商市场报告亮点

  • 由于人工智能在临床试验领域提供的各种应用以及製药公司越来越多地采用这些平台，预计到 2030 年市场规模将达到 78 亿美元。
  • 2021年二期临床试验领域市场规模压倒性优势，主要是由于同期活性药物研究增加所致。
  • 由于癌症发病率的增加和肿瘤学领域的药物研究增加，肿瘤学领域在 2021 年占据了市场主导地位。
  • 由于主要製药公司在药物开发中越来越多地采用人工智能技术，製药公司部门在市场上的利润份额最高。
  • 在北美，该地区的临床试验数量正在增加，人工智能平台和工具的采用正在扩大，在药物开发中基于人工智能的初创公司和公司数量正在增加，意识基于人工智能的工具和技术的数量正在增加，从多方面因素主导市场，2021年的收入份额达到43.8%。

目录

第 1 章调查方法及范围

  • 市场细分和范围
  • 市场定义
  • 调查方法
    • 资讯采购
      • 购买的数据库
      • GVR 内部数据库
    • 初步调查
  • 调查范围和先决条件
  • 数据源列表

第 2 章执行摘要

  • 市场展望
  • 细分市场展望

第 3 章全球基于人工智能的临床试验解决方案提供商的市场变量、趋势和范围

  • 渗透率和增长前景映射
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 全球基于人工智能的临床试验解决方案提供商市场分析工具
    • 行业分析-波特五力分析
      • 供应商议价能力
      • 买方的议价能力
      • 替代威胁
      • 来自新进入者的威胁
      • 竞争对手之间的敌对关係
    • PESTEL 分析
      • 政治局势
      • 经济和社会状况
      • 技术情况
      • 法律状况
      • 技术情况
    • 重大交易和战略联盟分析
  • COVID-19 对市场的影响

第 4 章基于AI的临床试验解决方案提供商市场：临床试验阶段估计和趋势分析

  • 定义和范围
  • 全球基于 AI 的临床试验解决方案提供商市场：2021 年和 2030 年临床试验阶段的市场份额分析
  • 第一阶段
    • 2016-2030 年第一阶段分析市场估计和预测（100 万美元）
  • 第二阶段
    • 2016-2030 年第二阶段分析市场估计和预测（100 万美元）
  • 第三阶段
    • 2016-2030 年 III 期分析市场估计和预测（100 万美元）

第 5 章基于 AI 的临床试验解决方案提供商市场：治疗应用的估计和趋势分析

  • 定义和范围
  • 全球基于 AI 的临床试验解决方案提供商市场：2021 年和 2030 年治疗应用市场份额分析
  • 肿瘤学
    • 2016-2030 年肿瘤学分析市场估计和预测（100 万美元）
  • 心血管疾病
    • 2016-2030 年心血管疾病分析市场估计和预测（100 万美元）
  • 神经系统疾病或神经系统疾病
    • 2016-2030 年神经系统疾病或状况分析市场估计/预测（100 万美元）
  • 代谢性疾病
    • 2016-2030 年代谢疾病分析市场估计/预测（100 万美元）
  • 传染病
    • 2016-2030 年传染病分析市场估计/预测（100 万美元）
  • 其他
    • 2016-2030 年其他分析市场估计/预测（100 万美元）

第 6 章基于AI的临床试验解决方案提供商市场：最终用途估计和趋势分析

  • 定义和范围
  • 全球基于 AI 的临床试验解决方案提供商市场：2020 年和 2030 年最终用途市场份额分析
  • 製药公司
    • 2016-2030 年製药公司的分析市场估计和预测（100 万美元）
  • 学术机构
    • 2016-2030 年学术机构分析市场估计/预测（100 万美元）
  • 其他
    • 2016-2030 年其他分析市场估计/预测（100 万美元）

第 7 章基于 AI 的临床试验解决方案提供商市场：区域估计/趋势分析、临床试验阶段、治疗和最终用途

  • 全球基于人工智能的临床试验解决方案提供商市场：区域变异性分析
  • 北美
    • 2016-2030 年北美基于 AI 的临床试验解决方案提供商市场估计和预测临床试验阶段、治疗应用和最终用途（100 万美元）
    • 美国
      • 2016-2030年美国基于AI的临床试验解决方案提供商、临床试验阶段、治疗应用以及市场估计和预测，2016-2030年（100万美元）
    • 加拿大
      • 2016-2030年加拿大基于AI的临床试验解决方案提供商、临床试验阶段、治疗应用以及市场估计和预测，2016-2030年（100万美元）
  • 欧洲
    • 2016-2030年欧洲基于AI的临床试验解决方案提供商、临床试验阶段、治疗应用以及市场估计和预测，2016-2030年（100万美元）
    • 英国
      • 2016-2030年英国基于AI的临床试验解决方案提供商、临床试验阶段、治疗应用以及市场估计和预测，2016-2030年（100万美元）
    • 德国
      • 2016-2030年德国基于AI的临床试验解决方案提供商市场估计和预测（100万美元）
    • 西班牙
      • 2016-2030年西班牙基于AI的临床试验解决方案提供商市场估计和预测（100万美元）
    • 法国
      • 2016-2030年法国基于AI的临床试验解决方案提供商、临床试验阶段、治疗应用以及市场估计和预测，2016-2030年（100万美元）
    • 义 大利
      • 2016-2030年意大利基于AI的临床试验解决方案提供商、临床试验阶段、治疗应用以及市场估计和预测，2016-2030年（100万美元）
    • 俄罗斯
      • 俄罗斯基于AI的临床试验解决方案提供商，市场估计和预测，2016-2030年（100万美元）
  • 亚太地区
    • 2016-2030 年亚太地区基于 AI 的临床试验解决方案提供商、市场估计/预测和临床试验阶段、治疗应用和最终用途预测（100 万美元）
    • 中国
      • 2016-2030年中国基于AI的临床试验解决方案提供商市场预估与预测（百万美元）
    • 日本
      • 2016-2030年日本基于AI的临床试验解决方案提供商市场预估与预测（100万美元）
    • 印度
      • 2016-2030年印度基于AI的临床试验解决方案提供商、临床试验阶段、治疗应用以及市场估计和预测，2016-2030年（100万美元）
    • 韩国
      • 2016-2030 年韩国基于 AI 的临床试验解决方案提供商的市场估计和预测（100 万美元）
    • 澳大利亚
      • 2016-2030年澳大利亚基于AI的临床试验解决方案提供商、临床试验阶段、治疗应用以及市场估计和预测，2016-2030年（100万美元）
  • 拉丁美洲
    • 拉丁美洲基于 AI 的临床试验解决方案提供商，市场估计和预测，2016-2030 年（100 万美元）
    • 巴西
      • 巴西基于 AI 的临床试验解决方案提供商，市场估计和预测，2016-2030 年（100 万美元）
    • 墨西哥
      • 2016-2030年墨西哥基于AI的临床试验解决方案提供商市场预估与预测（100万美元）
    • 阿根廷
      • 阿根廷基于AI的临床试验解决方案提供商，市场估计和预测，2016-2030年（100万美元）
  • 中东/非洲
    • 中东/非洲基于人工智能的临床试验解决方案提供商，市场估计和预测，2016-2030 年（100 万美元）
    • 南非
      • 2016-2030 年南非基于 AI 的临床试验解决方案提供商、市场估计和预测性临床试验阶段、治疗应用和最终用途（100 万美元）
    • 沙特阿拉伯
      • 沙特阿拉伯基于人工智能的临床试验解决方案提供商、市场估计和预测临床试验阶段、治疗应用和最终用途 2016-2030（100 万美元）
    • 阿拉伯联合酋长国
      • 阿拉伯联合酋长国基于人工智能的临床试验解决方案提供商、临床试验阶段、治疗和最终用途市场估计和预测，2016-2030 年（100 万美元）

第 8 章公司简介

  • Unlearn.AI, Inc.
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Saama Technologies
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Antidote Technologies, Inc.
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Exscientia
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Google Inc. (Verily)
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • IBM Watson
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • GNS Healthcare
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • BioSymetrics
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Euretos
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Koneksa Health
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Trials.Ai
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Ardigen
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Pharmaseal
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Halo Health Systems
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • DEEP LENS AI
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • CONSILX
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • AiCure, LLC
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • BioAge Labs, Inc.
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Symphony AI
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Median Technologies
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Intelligencia
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Mendel.ai
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Innoplexus
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Deep 6 AI
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
  • Phesi
    • 公司简介
    • 财务表现
    • 产品基准
    • 战略举措
Product Code: GVR-4-68039-456-6

AI-based Clinical Trials Solution Provider Market Growth & Trends:

The global AI-based clinical trials solution provider market size is expected to reach USD 7.8 billion by 2030 and is expected to expand at a CAGR of 22.0% over the forecast period, according to a new report by Grand View Research, Inc. AI is a versatile tool and is being increasingly utilized to improve the operational efficacy of drug studies and accelerate the drug discovery process. Also, it is highly adopted to minimize the cost of the drug development process. Various academia and pharmaceutical companies are actively adopting AI-based platforms and technologies. For instance, in January 2020, Bayer entered into a partnership with an AI-driven drug discovery company based in the UK to work on early research projects using the AI drug discovery platform. Furthermore, the initiatives by the public and private sectors to boost the R&D coupled with the diverse application provided by AI in the field of drug studies is impelling the growth.

Based on the phase of the clinical trial, Phase II dominated the market with a share of 47.2% in 2021 owing to the rising number of drug discoveries and a large number of studies active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the clinical trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase.

In 2021, based on therapeutic applications, oncology accounted for the highest revenue share in the AI-based clinical trials solution provider market. The increasing prevalence of cancer across the globe and the rising number of drug studies in the field of oncology is contributing to the adoption of AI enables technologies. Also, an increasing number of players are developing and adopting advanced oncology-based AI tools for drug studies, thereby propelling the segment growth.

In 2021, based on end-use, pharmaceutical companies accounted for the highest revenue share in the market. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify the new drug target and the overall process of drug development and drug trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendor for leveraging the AI technology for R&D and overall drug discovery process, thereby, impelling the growth.

North America dominated the market and accounted for revenue share of 43.8% in 2021. This dominance is attributed to the rising number of start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Also, the growing awareness of AI-based technologies and their adoption to enhance the drug studies' outcomes is impelling the market growth in the region. Furthermore, the supportive government initiatives and increasing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region.

The AI-based technologies witnessed a surge in their adoption due to the outburst of COVID-19. This increasing adoption of technologically advanced solutions for drug development and for the analyses of the recruited patient's data contributed to the upsurge in the adoption of AI-enabled solutions. Moreover, many drug development processes were on hold during the pandemic. Therefore, many key companies in the market shifted their focus on the utilization of AI-based solutions, thereby boosting decentralized drug trials. Furthermore, the effective analysis of a large amount of patient data through these solutions supported the market growth.

AI-based Clinical Trials Solution Provider Market Report Highlights:

  • The market size is anticipated to be valued at USD 7.8 billion by 2030, owing to various applications provided by AI in the field of clinical trials and the growing adoption of such platforms by pharmaceutical companies
  • The phase-II trials segment dominated the market in 2021, owing to the increasing number of active drug studies in this phase
  • The oncology segment dominated the market in 2021, owing to the rising prevalence of cancer and the growing number of drug studies in the oncology field
  • The pharmaceutical companies segment accounted for the highest revenue share in the market owing to the increasing adoption of artificial intelligence technologies for drug development by major pharmaceutical players
  • North America dominated the market and accounted for revenue share of 43.8% in 2021, owing to various factors including the increasing number of clinical trials in the region, growing adoption of artificial intelligence platforms and tools, rising number of start-ups and companies based on artificial intelligence in drug development and growing awareness regarding AI-based tools and technologies

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation and Scope
  • 1.2 Market Definition
  • 1.3 Research Methodology
    • 1.3.1 Information Procurement
      • 1.3.1.1 Purchased database
      • 1.3.1.2 GVR's internal database
    • 1.3.2 Primary Research
  • 1.4 Research Scope and Assumptions
  • 1.5 List of Data Sources

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook

Chapter 3 Global AI-based Clinical Trial Solution Providers Market Variables, Trends, & Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Market Restraint Analysis
  • 3.3 Global AI-based Clinical Trial Solution Providers Market Analysis Tools
    • 3.3.1 Industry Analysis - Porter's
      • 3.3.1.1 Bargaining power of the suppliers
      • 3.3.1.2 Bargaining power of the buyers
      • 3.3.1.3 Threats of substitution
      • 3.3.1.4 Threats from new entrants
      • 3.3.1.5 Competitive rivalry
    • 3.3.2 PESTEL Analysis
      • 3.3.2.1 Political landscape
      • 3.3.2.2 Economic and Social landscape
      • 3.3.2.3 Technology landscape
      • 3.3.2.4 Legal landscape
      • 3.3.2.5 Technology landscape
    • 3.3.3 Major Deals & Strategic Alliances Analysis
  • 3.4 COVID-19 Impact on the market

Chapter 4 AI-based Clinical Trial Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis

  • 4.1 Definitions & Scope
  • 4.2 Global AI-based Clinical Trial Solution Providers Market: Clinical Trial Phase Market Share Analysis, 2021 and 2030
  • 4.3 Phase-I
    • 4.3.1 Phase-I analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
    • 4.3.2 Phase-II
      • 4.3.2.1 Phase-II analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
    • 4.3.3 Phase-III
      • 4.3.3.1 Phase-III analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)

Chapter 5 AI-based Clinical Trial Solution Providers Market: Therapeutic Application Estimates & Trend Analysis

  • 5.1 Definitions & Scope
  • 5.2 Global AI-based Clinical Trial Solution Providers Market: Therapeutic Application Market Share Analysis, 2021 and 2030
  • 5.3 Oncology
    • 5.3.1 Oncology analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.4 Cardiovascular Diseases
    • 5.4.1 Cardiovascular Diseases analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.5 Neurological Diseases or Conditions
    • 5.5.1 Neurological Diseases or Conditions analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.6 Metabolic Diseases
    • 5.6.1 Metabolic Diseases analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.7 Infectious Diseases
    • 5.7.1 Infectious Diseases analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.8 Others
    • 5.8.1 Others analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)

Chapter 6 AI-based Clinical Trial Solution Providers Market: End-Use Estimates & Trend Analysis

  • 6.1 Definitions & Scope
  • 6.2 Global AI-based Clinical Trial Solution Providers Market: End-Use Market Share Analysis, 2020 and 2030
  • 6.3 Pharmaceutical Companies
    • 6.3.1 Pharmaceutical Companies analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 6.4 Academia
    • 6.4.1 Academia analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 6.5 Others
    • 6.5.1 Others analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)

Chapter 7 AI-based Clinical Trial Solution Providers Market: Regional Estimates & Trend Analysis, By Clinical Trial Phase, Therapeutic Application & End-Use

  • 7.1 Global AI-based Clinical Trial Solution Providers Market: Regional Movement Analysis
  • 7.2 North America
    • 7.2.1 North America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Canada AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.2 U.K.
      • 7.3.2.1 U.K. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.3 Germany
      • 7.3.3.1 Germany AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.4 Spain
      • 7.3.4.1 Spain AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.5 France
      • 7.3.5.1 France AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.6 Italy
      • 7.3.6.1 Italy AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.7 Russia
      • 7.3.7.1 Russia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.2 China
      • 7.4.2.1 China AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.3 Japan
      • 7.4.3.1 Japan AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.4 India
      • 7.4.4.1 India AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.6 Australia
      • 7.4.6.1 Australia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
  • 7.6 MEA
    • 7.6.1 MEA AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.6.4 UAE
      • 7.6.4.1 UAE AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Unlearn.AI, Inc.
    • 8.1.1 Company Overview
    • 8.1.2 Financial Performance
    • 8.1.3 Product Benchmarking
    • 8.1.4 Strategic Initiatives
  • 8.2 Saama Technologies
    • 8.2.1 Company Overview
    • 8.2.2 Financial Performance
    • 8.2.3 Product Benchmarking
    • 8.2.4 Strategic Initiatives
  • 8.3 Antidote Technologies, Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Financial Performance
    • 8.3.3 Product Benchmarking
    • 8.3.4 Strategic Initiatives
  • 8.4 Exscientia
    • 8.4.1 Company Overview
    • 8.4.2 Financial Performance
    • 8.4.3 Product Benchmarking
    • 8.4.4 Strategic Initiatives
  • 8.5 Google Inc. (Verily)
    • 8.5.1 Company Overview
    • 8.5.2 Financial Performance
    • 8.5.3 Product Benchmarking
    • 8.5.4 Strategic Initiatives
  • 8.6 IBM Watson
    • 8.6.1 Company Overview
    • 8.6.2 Financial Performance
    • 8.6.3 Product Benchmarking
    • 8.6.4 Strategic Initiatives
  • 8.7 GNS Healthcare
    • 8.7.1 Company Overview
    • 8.7.2 Financial Performance
    • 8.7.3 Product Benchmarking
    • 8.7.4 Strategic Initiatives
  • 8.8 BioSymetrics
    • 8.8.1 Company Overview
    • 8.8.2 Financial Performance
    • 8.8.3 Product Benchmarking
    • 8.8.4 Strategic Initiatives
  • 8.9 Euretos
    • 8.9.1 Company Overview
    • 8.9.2 Financial Performance
    • 8.9.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives
  • 8.10 Koneksa Health
    • 8.10.1 Company Overview
    • 8.10.2 Financial Performance
    • 8.10.3 Product Benchmarking
    • 8.10.4 Strategic Initiatives
  • 8.11 Trials.Ai
    • 8.11.1 Company Overview
    • 8.11.2 Financial Performance
    • 8.11.3 Product Benchmarking
    • 8.11.4 Strategic Initiatives
  • 8.12 Ardigen
    • 8.12.1 Company Overview
    • 8.12.2 Financial Performance
    • 8.12.3 Product Benchmarking
    • 8.12.4 Strategic Initiatives
  • 8.13 Pharmaseal
    • 8.13.1 Company Overview
    • 8.13.2 Financial Performance
    • 8.13.3 Product Benchmarking
    • 8.13.4 Strategic Initiatives
  • 8.14 Halo Health Systems
    • 8.14.1 Company Overview
    • 8.14.2 Financial Performance
    • 8.14.3 Product Benchmarking
    • 8.14.4 Strategic Initiatives
  • 8.15 DEEP LENS AI
    • 8.15.1 Company Overview
    • 8.15.2 Financial Performance
    • 8.15.3 Product Benchmarking
    • 8.15.4 Strategic Initiatives
  • 8.16 CONSILX
    • 8.16.1 Company Overview
    • 8.16.2 Financial Performance
    • 8.16.3 Product Benchmarking
    • 8.16.4 Strategic Initiatives
  • 8.17 AiCure, LLC
    • 8.17.1 Company Overview
    • 8.17.2 Financial Performance
    • 8.17.3 Product Benchmarking
    • 8.17.4 Strategic Initiatives
  • 8.18 BioAge Labs, Inc.
    • 8.18.1 Company Overview
    • 8.18.2 Financial Performance
    • 8.18.3 Product Benchmarking
    • 8.18.4 Strategic Initiatives
  • 8.19 Symphony AI
    • 8.19.1 Company Overview
    • 8.19.2 Financial Performance
    • 8.19.3 Product Benchmarking
    • 8.19.4 Strategic Initiatives
  • 8.20 Median Technologies
    • 8.20.1 Company Overview
    • 8.20.2 Financial Performance
    • 8.20.3 Product Benchmarking
    • 8.20.4 Strategic Initiatives
  • 8.21 Intelligencia
    • 8.21.1 Company Overview
    • 8.21.2 Financial Performance
    • 8.21.3 Product Benchmarking
    • 8.21.4 Strategic Initiatives
  • 8.22 Mendel.ai
    • 8.22.1 Company Overview
    • 8.22.2 Financial Performance
    • 8.22.3 Product Benchmarking
    • 8.22.4 Strategic Initiatives
  • 8.23 Innoplexus
    • 8.23.1 Company Overview
    • 8.23.2 Financial Performance
    • 8.23.3 Product Benchmarking
    • 8.23.4 Strategic Initiatives
  • 8.24 Deep 6 AI
    • 8.24.1 Company Overview
    • 8.24.2 Financial Performance
    • 8.24.3 Product Benchmarking
    • 8.24.4 Strategic Initiatives
  • 8.25 Phesi
    • 8.25.1 Company Overview
    • 8.25.2 Financial Performance
    • 8.25.3 Product Benchmarking
    • 8.25.4 Strategic Initiatives

List of Tables

  • Table 1 North America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 2 North America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 3 North America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 4 U.S. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 5 U.S. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 6 U.S. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 7 Canada AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 8 Canada AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 9 Canada AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 10 Europe AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 11 Europe AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 12 Europe AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 13 U.K. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 14 U.K. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 15 U.K. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 16 Germany AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 17 Germany AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 18 Germany AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 19 Spain AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 20 Spain AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 21 Spain AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 22 France AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 23 France AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 24 France AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 25 Italy AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 26 Italy AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 27 Italy AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 28 Russia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 29 Russia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 30 Russia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 31 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 32 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 33 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 34 China AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 35 China AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 36 China AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 37 Japan AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 38 Japan AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 39 Japan AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 40 India AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 41 India AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 42 India AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 43 Australia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 44 Australia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 45 Australia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table46 South Korea AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 47 South Korea AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 48 South Korea AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 49 Latin America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 50 Latin America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 51 Latin America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 52 Brazil AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 53 Brazil AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 54 Brazil AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 55 Mexico AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 56 Mexico AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 57 Mexico AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 58 Argentina AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 59 Argentina AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 60 Argentina AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 61 Middle East & Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 62 Middle East & Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 63 Middle East & Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 64 South Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 65 South Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 66 South Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 67 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 68 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 69 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 70 UAE AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 71 UAE AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 72 UAE AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 AI-based Clinical Trial Solution Providers market snapshot, 2021, (USD Million)
  • Fig. 6 AI-based Clinical Trial Solution Providers market trends & outlook
  • Fig. 7 Penetration & growth prospect mapping
  • Fig. 8 Market driver analysis (Current & future impact)
  • Fig. 9 Market restraint analysis (Current & future impact)
  • Fig. 10 AI-based Clinical Trial Solution Providers market, clinical trial phase outlook key takeaways (USD Million)
  • Fig. 11 AI-based Clinical Trial Solution Providers market: clinical trial phase movement analysis (USD Million), 2021 & 2030
  • Fig. 12 Phase-I Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 13 Phase-II Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 14 Phase-III Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 15 AI-based Clinical Trial Solution Providers market, therapeutic application outlook key takeaways (USD Million)
  • Fig. 16 AI-based Clinical Trial Solution Providers market: therapeutic application movement analysis (USD Million), 2020 & 2030
  • Fig. 17 Oncology Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 18 Cardiovascular diseases Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 19 Neurological Diseases or Conditions Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 20 Metabolic Diseases Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 21 Infectious Diseases Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 22 Other Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 23 AI-based Clinical Trial Solution Providers market, end-use outlook key takeaways (USD Million)
  • Fig. 24 AI-based Clinical Trial Solution Providers market: end-use movement analysis (USD Million), 2020 & 2030
  • Fig. 25 Pharmaceutical companies Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 26 Academia Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 27 Others Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 28 AI-based Clinical Trial Solution Providers market, regional outlook key takeaways (USD Million)
  • Fig. 29 AI-based Clinical Trial Solution Providers market: regional movement analysis (USD Million), 2020 & 2030
  • Fig. 30 North America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 31 U.S. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 32 Canada AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 33 Europe AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 34 U.K AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 35 Germany AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 36 Spain AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 37 France AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 38 Italy AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 39 Russia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 40 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 41 China AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 42 Japan AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 43 India AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 44 South Korea AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 45 Australia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 46 Latin America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 47 Brazil AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 48 Mexico AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 49 Argentina AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 50 MEA AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 51 South Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 53 UAE AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)